Long road towards effective HER3 targeting in breast cancer
-
Published:2024-09
Issue:
Volume:129
Page:102786
-
ISSN:0305-7372
-
Container-title:Cancer Treatment Reviews
-
language:en
-
Short-container-title:Cancer Treatment Reviews
Author:
Papa Francesca, Grinda Thomas, Rassy Elie, Cheickh-Hussin Rasha, Ribeiro Joana, Antonuzzo Lorenzo, Pistilli BarbaraORCID
Reference90 articles.
1. A. Ocana, F. Vera-Badillo, B. Seruga, A. Templeton, A. Pandiella, e E. Amir, «HER3 overexpression and survival in solid tumors: A meta-analysis», Journal of the National Cancer Institute, vol. 105, fasc. 4. pp. 266–273, febbraio 2013. doi: 10.1093/jnci/djs501. 2. N. Jiang, N. F. Saba, e Z. G. Chen, «Advances in Targeting HER3 as an Anticancer Therapy», Chemotherapy Research and Practice, vol. 2012, pp. 1–9, nov. 2012, doi: 10.1155/2012/817304. 3. Molecular targeting therapy against egfr family in breast cancer: Progress and future potentials;Maennling;Cancers,2019 4. M. J. Wieduwilt e M. M. Moasser, «The epidermal growth factor receptor family: Biology driving targeted therapeutics», Cellular and Molecular Life Sciences, vol. 65, fasc. 10, pp. 1566–1584, mag. 2008, doi: 10.1007/s00018-008-7440-8. 5. H. Lyu, A. Han, E. Polsdofer, S. Liu, e B. Liu, «Understanding the biology of HER3 receptor as a therapeutic target in human cancer», Acta Pharmaceutica Sinica B, vol. 8, fasc. 4. Chinese Academy of Medical Sciences, pp. 503–510, luglio 2018. doi: 10.1016/j.apsb.2018.05.010.
|
|